Compare

Fresenius Medical Care AG/€FME

1D1W1M3M6MYTD1Y5YMAX

About Fresenius Medical Care AG

Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.
Ticker
€FME
Sector
Health
Primary listing
XETRA
Employees
107,226
Headquarters
Bad Homburg, Germany
Website
www.freseniusmedicalcare.com

FME Metrics

BasicAdvanced
€9.9B
11.24
€3.35
0.83
€1.49
3.96%

What the Analysts think about FME

Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.
Analyst projections of the future price of Fresenius Medical Care AG stock.

Bulls say / Bears say

Underlying profitability strengthened: second-quarter operating income excluding special items rose 23% at constant currency, and the margin expanded to 11.7% from 9.9%. Growth across all operating segments supports the case that the improvement is not confined to one business. (Fresenius Medical Care)
Cost cutting and clinic consolidation could support further margin gains: the transformation programme delivered €67 million of additional savings in Q2, and the company expects total FME25+ savings of €1.2 billion by the end of 2027. It has also completed its planned exit from around 100 selected US clinics. (Fresenius Medical Care)
The 5008X system offers a product and treatment growth opportunity as the US rollout scales: it was in 227 clinics by late July and had supported more than 600,000 treatments. Wider adoption could strengthen equipment sales and the company’s high-volume haemodiafiltration offering. (Fresenius Medical Care)
US treatment volumes are weak, and management identified a failure to convert patient referrals into treatments. Same-market treatment growth was -0.9% in Q2, and the company expects the 2026 rate to stay around that level while corrective work takes time. (Fresenius Medical Care)
The China portfolio reset brings near-term execution and earnings costs: Fresenius plans to exit peritoneal dialysis and discontinue its 4008A system there, with about €110 million of one-off costs expected in Q3. The company says the changes should not materially affect future China revenue, but the charge will weigh on reported results. (PR Newswire)
Part of the recent earnings strength relied on TDAPA reimbursement benefits that are set to fade: management cited about €80 million of year-on-year support in Q2 and expects TDAPA to become a headwind in the third and fourth quarters. That makes the near-term profit growth harder to sustain. (Fresenius Medical Care)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.

FME Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

FME Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing FME

AllEURGBPUSD
Funds
Fund name
Fund size
€FME weighting
iShares DivDAX€EXSB
€562M1.39%
iShares EURO STOXX Mid€DJMC
€572M0.95%
iShares EURO STOXX Mid Cap£DJMC
£491M0.95%
iShares Dax ESG€EXIA
€127M0.66%
iShares Edge MSCI Europe Value Factor€CEMS
€2.6B0.51%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.